Latest Conference Articles

Jordan Axelrad, MD, MPH: Addressing Nonadherence to IBD Therapies with Remote Monitoring

At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.

Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD

Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.

Low-Dose CAR-T Shows Efficacy in Pediatric Systemic Lupus Erythematosus

This discussion with Murina covers several tips for dermatologists to implement, 1 of which touched on omega-3 supplementation for ocular rosacea.

By Victoria Johnson

Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

By Connor Iapoce

Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD

At AAO 2024, Wykoff discussed first-time extended results from AMARONE showing Restoret’s effectiveness in improving outcomes for patients with DME and nAMD.

Second-Line Obeticholic Acid for PBC Used Infrequently and with Delays

In her Fall Clinical interview, Murina highlighted several key takeaways related to her talk titled ‘Managing Psoriasis with Oral Therapy: 2024 & Beyond.’

Hormone Replacement Therapy Linked to Greater IBS, Gastric Motility Disorder Risk

Data from ACG 2024 show only 1 in 12 patients eligible for second-line PBC therapy are actually doing receiving it—and it may take up to a year to initiate.

ChatGPT Reliable for Gastrointestinal Disease-Based Diet Advice

Jacqueline Khalil, DO, reviews findings from 2 studies about the association between hormone replacement therapy with IBS and gastric motility disorders.

GLP-1 RAs Increase Residual Gastric Content But Pose Low Medical Risk During Endoscopy

ChatGPT may provide helpful information around gastroparesis, IBS and celiac disease diets, according to findings from a new study.

2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD

Braden Kuo, MD, explains how GLP-1 RA use increases residual gastric content but does not significantly impact negative endoscopy outcomes.

Abdul Abdellatif, MD: Early Osteopenia Interventions Needed for Patients With Kidney Disease and Gout

This interview from Fall Clinical covers 2 additional tips for clinical practice as well as unmet needs among patients.

By Victoria Johnson

Brian Lacy, MD, PhD: Profiling Gastric Activity Variations with Multiday Testing

Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.

Brian Lacy, MD, PhD | Credit: Mayo Clinic

Christine N. Kay, MD: TEASE Trials Show Promise of Gildeuretinol for Stargardt

Lacy explains the potential value of an ambulatory wireless patch test for identifying unique gastric activity patterns and individualizing patient care.

Christine N. Kay, MD | Image Credit: Atsena Therapeutics

By Connor Iapoce

Ronnie Fass, MD: On-Demand Vonoprazan for Non-Erosive GERD “Within Our Reach”

At AAO 2024, Kay presented an overview of gildeuretinol, an oral vitamin A derivative offering hope for patients with Stargardt disease.

Discussing Unmet Needs for Skin Cancer with Laura K. Ferris, MD, PhD, and Neal Bhatia, MD

Fass reviews findings from a post hoc analysis of a phase 2 trial suggesting the value of vonoprazan as an on-demand NERD treatment.

Carla Nester, MD: 12-Month Data Informs Potential of Iptacopan in C3 Glomerulopathy

In this interview at Fall Clinical Dermatology, Ferris and Bhatia highlighted several elements of skin cancer detection and management as well as unmet needs of patients.

By Patrick Campbell

12-Month APPEAR-C3G Data Highlight Potential of Iptacopan in C3 Glomerulopathy

Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.

Carla Nester, MD | Credit: University of Iowa

By Patrick Campbell

Basile Njei, MD, MPH, PhD: Increasing Lean MASLD Awareness, Improving Screening

The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.

Basile Njei, MD, MPH, PhD | Credit: Yale

2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD

Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.

Vitamin D Deficiency Linked to Worse IBD Hospital Outcomes

This Fall Clinical Dermatology Conference interview with Song features a discussion regarding several useful clinical pearls for dermatologists.

Timothy Ritter, MD: Real-World Data Supporting Fecal Microbiota for Recurrent C Diff

New ACG 2024 data show patients with both IBD and vitamin D deficiency face longer, more expensive hospital stays, as well as risk of colectomy.

Timothy Ritter, MD | Credit: Texas Digestive Disease Consultants

AIMS65 Could Predict Treated Gastrointestinal Bleed Death, Rebleed Risks

Ritter reviews findings from 2 real-world studies supporting the safety and efficacy of live-jslm (Rebyota) for recurrent C Diff infection.

Zegocractin Significantly Improves Acute Pancreatitis Symptoms in Phase 2 CARPO

New late-breaking ACG 2024 data supports AIMS65 as a risk factor tool for patients undergoing anticoagulant reversal.

Infliximab Improves Ulcerative Colitis, Crohn's Disease Regardless of Immunosuppressants

The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.

Collaboration, Intralesional Therapies for Skin Cancer, with Laura K. Ferris, MD, PhD, and Neal Bhatia, MD

Post hoc analyses from the LIBERTY trials support infliximab as either a monotherapy or combination therapy for ulcerative colitis or Crohn's disease.

What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?

This interview features a discussion with Bhatia and Ferris regarding the necessity of collaboration between dermatologists and oncologists for skin cancer.

Brian Lacy, MD, PhD: Rethinking Motility Testing with a Noninvasive Wireless Patch System

In this interview, Neal Bhatia, MD, and Laura Korb Ferris, MD, PhD, spoke on their Fall Clinical Conference talk titled ‘Beyond the Biopsy: Other Methods To Help Us Manage Skin Cancer.’

Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024

Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.

By Brendon Neuen, MBBS, PhD
Shikha Wadhwani, MD, MS

New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD

Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.